Immune-Checkpoint Blockade Therapy in Lymphoma
نویسندگان
چکیده
منابع مشابه
Immune Checkpoint Blockade in Cancer Therapy.
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory appr...
متن کاملUpdate on checkpoint blockade therapy for lymphoma
Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse mechanisms aimed at subverting the host anti-tumor immune response. Tumor immune evasion pathways have been most thoroughly studied in solid tumors. However, emerging data has demonstrated that malignancies of hematopoietic origin are also able to co-opt their local environment in order t...
متن کاملCombination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
In healthy individuals, immune-checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system. Over the past years, immune-checkpoint blockade of cytotoxic T lymphocyte antigen-4 and programed death-1 emerged as promising strategies to activate antitumor cytotoxic T cell response...
متن کاملImmune checkpoint blockade therapy for bladder cancer treatment
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune checkpoints have been recently been applied to many aggressive cancers and changed interventions of urological cancers including advanced bladder cancer. The applied inhibition of PD-1-PD-L1 interactio...
متن کاملCorticosteroids and immune checkpoint blockade
checkpoint blockade to stimulate the immune response have demonstrated promising outcomes in advanced malignancies [1]. As a result, novel cancer immunotherapy was named a scientific breakthrough of the year in 2013 by Science. Consistent with its mechanism of action of de novo stimulation or enhancement of pre-existing T cell responses, a number of immune-related adverse events (irAEs) have be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Molecular Sciences
سال: 2020
ISSN: 1422-0067
DOI: 10.3390/ijms21155456